An immuno-modulatory phosphorus-based dendrimer for the treat ment of Multiple Sclerosis

DENDRI'MS est accrédité par Lyonbiopôle

Identity card

Global budget: 1500 k€

Public funding: 660 k€

Public funders: ANR, Agence Nationale de la Recherche

Call for projects: ANR (ANR2011 - RPIB)

Year start: 2011

Completed project (2015-06)

Accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Human Medicines

Application fields: Autoimmune diseases, Inflammatory diseases

Technological approaches / Keywords: Chemotherapy, Nanobiotechnology

Stage of development at the beginning of the project: Preclinical development


Based on our previous findings that phosphorus-based dendrimers have anti-inflammatory and immuno-modulatory properties toward the human immune system, our overall project is to develop these innovative molecules as new drug-candidates for the treatment of Chronic Inflammatory Diseases such as Rheumatoid Arthritis and Multiple Sclerosis. In the DENDRI’MS project we plan to prove the efficacy of the molecule in animal models of Multiple Sclerosis (mice and non-human primates), and to assess the general safety and the immuno-safety of the molecule.


The objectives of this project are: -          to validate dendrimer ABP as an innovative drug-candidate in MS with a Proof of Concept in mouse and non-human primate models of EAE; -          to depict the immunological properties of dendrimer ABP in animal models, including its Blood-Brain Barrier crossing property to directly reach the CNS; -          to address immuno-safety concerns regarding dendrimer ABP in a non-human primate model and propose validated / standardized procedures to evaluate immuno-safety and toxicology of nano-compounds.

Innovative assets
Actual results

Innovative assets

During the DENDRI'MS project, we will: - inject for the first time a dendrimer in non-human primates via a systemic route of administration to perform a subchronic toxicity assay; - set up a model of Multiple Sclerosis in non-human primates to prove the efficacy of the ABP dendrimer to treat the disease.